Novel c-CBL and CBL-b ubiquitin ligase mutations in human acute myeloid leukemia

Blood

Volumn 110, Issue 3, 2007, Pages 1022-1024

  Caligiuri, Michael A ^a,b,c   Briesewitz, Roger ^a,b   Yu, Jianhua ^a   Wang, Lisheng ^a   Wei, Min ^b   Arnoczky, Kristy J ^a   Marburger, Trent B ^c   Wen, Jing ^b   Perrotti, Danilo ^a,b   Bloomfield, Clara D ^b,c   Whitman, Susan P ^b,c  

^a OHIO STATE UNIVERSITY   (United States)

^b OHIO STATE UNIVERSITY   (United States)

^c THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CBL PROTEIN; MUTANT PROTEIN; SMALL INTERFERING RNA; UBIQUITIN PROTEIN LIGASE;

ACUTE GRANULOCYTIC LEUKEMIA; ALPHA HELIX; ARTICLE; CANCER GENETICS; CBL B GENE; CBL GENE; CONTROLLED STUDY; GENE MUTATION; HUMAN; HUMAN CELL; MISSENSE MUTATION; PRIORITY JOURNAL; PROTEIN ANALYSIS; RNA SPLICING;

EID: 34547950568     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2006-12-061176     Document Type: Article

References (24)

1. Ryan PE, Davies GC, Nau MM, Lipkowitz S. Regulating the regulator: negative regulation of Cbl ubiquitin ligases. Trends Biochem Sci. 2006;31:79-88.
2. Thien CB, Langdon WY. c-Cbl and Cbl-b ubiquitin ligases: substrate diversity and the negative regulation of signalling responses. Biochem J. 2005;391:153-166.
3. Smit L, Borst J. The Cbl family of signal transduction molecules. Crit Rev Oncogen. 1997;8:359-379.
4. Liu YC, Altman A. Cbl: complex formation and functional implications. Cell Signal. 1998;10:377-385.
5. Langdon WY, Hartley JW, Klinken SP, Ruscetti SK, Morse HC III. v-cbl, an oncogene from a dual-recombinant murine retrovirus that induces early B-lineage lymphomas. Proc Natl Acad Sci U S A. 1989;86:1168-1172.
6. Andoniou CE, Thien CB, Langdon WY. Tumour induction by activated abl involves tyrosine phosphorylation of the product of the cbl oncogene. EMBO J. 1994;13:4515-4523.
7. Bisson SA, Ujack EE, Robbins SM. Isolation and characterization of a novel, transforming allele of the c-Cbl proto-oncogene from a murine macrophage cell line. Oncogene. 2002;21:3677-3687.
8. Thien CB, Langdon WY. Cbl: many adaptations to regulate protein tyrosine kinases. Nat Rev Mol Cell Biol. 2001;2:294-307.
9. Blake TJ, Langdon WY. A rearrangement of the c-cbl proto-oncogene in HUT78 T-lymphoma cells results in a truncated protein. Oncogene. 1992;7:757-762.
10. Fu JF, Hsu JJ, Tang TC, Shih LY. Identification of CBL, a proto-oncogene at 11q23.3, as a novel MLL fusion partner in a patient with de novo acute myeloid leukemia. Genes Chromosomes Cancer. 2003;37:214-219.
11. Shih LY, Liang DC, Fu JF, et al. Characterization of fusion partner genes in 114 patients with de novo acute myeloid leukemia and MLL rearrangement. Leukemia. 2006;20:218-223.
12. Wagner EJ, Baraniak AP, Sessions OM, Mauger D, Moskowitz E, Garcia-Blanco MA. Characterization of the intronic splicing silencers flanking FGFR2 exon IIIb. J Biol Chem. 2005;280:14017-14027.
13. Kalnina Z, Zayakin P, Silina K, Line A. Alterations of pre-mRNA splicing in cancer. Genes Chromosomes Cancer. 2005;42:342-357.
14. Zheng N, Wang P, Jeffrey PD, Pavletich NP. Structure of a c-Cbl-UbcH7 complex: RING domain function in ubiquitin-protein ligases. Cell. 2000;102:533-539.
15. Levkowitz G, Waterman H, Ettenberg SA, Katz M, et al. Ubiquitin ligase activity and tyrosine phosphorylation underlie suppression of growth factor signaling by c-Cbl/Sli-1. Mol Cell. 1999;4:1029-1040.
16. Galisteo ML, Dikic I, Batzer AG, Langdon WY, Schlessinger J. Tyrosine phosphorylation of the c-cbl proto-oncogene protein product and association with epidermal growth factor (EGF) receptor upon EGF stimulation. J Biol Chem. 1995;270:20242-20245.
17. Miyake S, Mullane-Robinson KP, Lill NL, Douillard P, Band H. Cbl-mediated negative regulation of platelet-derived growth factor receptor-dependent cell proliferation: a critical role for Cbl tyrosine kinase-binding domain. J Biol Chem. 1999;274:16619-16628.
18. Miyake S, Lupher ML Jr, Druker B, Band H. The tyrosine kinase regulator Cbl enhances the ubiquitination and degradation of the platelet-derived growth factor receptor alpha. Proc Natl Acad Sci U S A. 1998;95:7927-7932.
19. Kassenbrock CK, Anderson SM. Regulation of ubiquitin protein ligase activity in c-Cbl by phosphorylation-induced conformational change and constitutive activation by tyrosine to glutamate point mutations. J Biol Chem. 2004;279:28017-28027.
20. Thien CB, Walker F, Langdon WY. RING finger mutations that abolish c-Cbl-directed polyubiquitination and downregulation of the EGF receptor are insufficient for cell transformation. Mol Cell. 2001;7:355-365.
21. Hamilton E, Miller KM, Helm KM, Langdon WY, Anderson SM. Suppression of apoptosis induced by growth factor withdrawal by an oncogenic form of c-Cbl. J Biol Chem. 2001;276:9028-9037.
22. Levkowitz G, Oved S, Klapper LN, et al. c-Cbl is a suppressor of the neu oncogene. J Biol Chem. 2000;275:35532-35539.
23. Zeng S, Xu Z, Lipkowitz S, Longley JB. Regulation of stem cell factor receptor signaling by Cbl family proteins (Cbl-b/c-Cbl). Blood. 2005;105:226-232.
24. Sargin B, Choudhary C, Crosetto N, et al. Flt3-dependent transformation by inactivating c-Cbl mutations in AML. Blood. Prepublished on May 14, 2007, as DOI 10.1182/blood-2007-01-066076.